Physician profile
Martha Brooks
NPI 1760431498
$1,125.12
in general payments reported to CMS, 2019-2025
26 companies · $914 in 2025
The $914 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $211 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $173.29 | 2024-2025 | Evenity, Krystexxa, Tavneos |
| Viiv Healthcare Company | $108.00 | 2025 | Cabenuva, Rukobia, Apretude |
| Theratechnologies INC. | $79.54 | 2025 | Egrifta, Trogarzo |
| Merck Sharp & Dohme LLC | $74.84 | 2024-2025 | Zerbaxa, Pifeltro, Delstrigo |
| Abbvie INC. | $72.06 | 2025 | |
| Ucb, INC. | $69.72 | 2024-2025 | Bimzelx |
| Glaxosmithkline, LLC. | $60.02 | 2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $54.87 | 2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.67 | 2024-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $41.23 | 2024-2025 | Vowst |
| Novartis Pharmaceuticals Corporation | $32.65 | 2025 | |
| Esperion Therapeutics, INC. | $29.73 | 2025 | Nexletol |
| Kyowa Kirin, INC. | $27.39 | 2025 | |
| Janssen Biotech, INC. | $27.16 | 2025 | Tremfya |
| Pharmacosmos Therapeutics INC. | $24.77 | 2025 | Monoferric |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Invivyd INC | $23.74 | 2025 | Pemgarda |
| Bayer Healthcare Pharmaceuticals INC. | $23.02 | 2025 | |
| Ardelyx, INC. | $21.65 | 2025 | Ibsrela |
| Organon LLC | $21.60 | 2025 | Hadlima |
| Scpharmaceuticals INC. | $19.22 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.72 | 2025 | Saphnelo |
| Apellis Pharmaceuticals, INC. | $17.54 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.98 | 2025 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.67 | 2025 | |
| Melinta Therapeutics, LLC | $14.23 | 2025 | Rezzayo |
| Novo Nordisk INC | $13.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.